Harrow Health, Inc. Overview
Pro stress-test →Harrow Health is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products. The company operates primarily through its subsidiary ImprimisRx, a compounding pharmacy that creates custom-formulated medications tailored to specific patient needs, often at prices more competitive than traditional offerings.
Strategic Profile
Pro stress-test →By emphasizing a direct-to-prescriber model, the company circumvents many traditional barriers and costs associated with large pharmaceutical firms, allowing for reduction in drug prices and improved distribution efficiency. Harrow Health is actively involved in acquiring and licensing innovative ophthalmic technologies and products, with a multi-pronged approach that drives revenue through direct sales while strengthening its position by investing in emerging therapies.
Competitive Landscape
Pro stress-test →Harrow competes in the specialized ophthalmology pharmaceutical segment against larger diversified pharma companies. Analyst price targets range up to $69, with multiple Buy ratings from major firms including William Blair, BTIG, and H.C. Wainwright. The direct-to-prescriber, high-margin compounding model provides differentiation versus traditional pharmaceutical distribution.
Industry Context
Harrow Health, Inc. operates in Specialty Pharmaceuticals - Ophthalmology.
Key facts
Founded: 2006 · Headquarters: San Diego, US · Revenue: $350M-$365M · Market cap: $1.85B